Literature DB >> 646348

Amphotericin B pharmacokinetics in humans.

A J Atkinson, J E Bennett.   

Abstract

The pharmacokinetics of amphotericin B were studied in two patients at the conclusion of long-term therapy for disseminated histoplasmosis. The distribution kinetics of this drug were adequately described by a three-compartment mamillary model with a total distribution volume averaging 4 liters/kg. The elimination phase half-life of amphotericin B was approximately 15 days, reflecting slow release of amphotericin B from a peripheral compartment. In accordance with previous reports, renal excretion accounted for only 3% of total amphotericin B elimination. The pharmacokinetic model for one of the patients also was used to compare the simulated amphotericin B serum levels that would be expected if initial therapy followed two recommended regimens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 646348      PMCID: PMC352226          DOI: 10.1128/AAC.13.2.271

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors:  D B LOURIA
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1958-05

Review 2.  Chemotherapy of systemic mycoses (first of two parts).

Authors:  J E Bennett
Journal:  N Engl J Med       Date:  1974-01-03       Impact factor: 91.245

3.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

4.  Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man.

Authors:  E R Block; J E Bennett; L G Livoti; W J Klein; R R MacGregor; L Henderson
Journal:  Ann Intern Med       Date:  1974-05       Impact factor: 25.391

5.  Increased permeability of human erythrocytes induced by amphotericin B.

Authors:  W T Butler; E Cotlove
Journal:  J Infect Dis       Date:  1971-04       Impact factor: 5.226

6.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

Review 7.  Plasma and tissue protein binding of drugs in pharmacokinetics.

Authors:  W J Jusko; M Gretch
Journal:  Drug Metab Rev       Date:  1976       Impact factor: 4.518

8.  The effect of diphenylhydantoin on thyroxine metabolism in man.

Authors:  P R Larsen; A J Atkinson; H N Wellman; R E Goldsmith
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

9.  Amphotericin B therapy in an anephric patient.

Authors:  H A Feldman; J D Hamilton; R A Gutman
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

10.  Amphotericin B serum concentrations during therapy.

Authors:  B T Fields; J H Bates; R S Abernathy
Journal:  Appl Microbiol       Date:  1970-06
View more
  57 in total

1.  Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers.

Authors:  S W Sanders; K N Buchi; M S Goddard; J K Lang; K G Tolman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Ali Khamesipour; Mostafa Haji Molla Hoseini; Nariman Mosaffa; Ali Anissian; Amitis Ramezani
Journal:  J Mater Sci Mater Med       Date:  2018-07-28       Impact factor: 3.896

4.  Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans.

Authors:  F Bistoni; A Vecchiarelli; R Mazzolla; P Puccetti; P Marconi; E Garaci
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

6.  Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum.

Authors:  E Martin; U Schlasius; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 7.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

Review 8.  Antifungals in systemic neonatal candidiasis.

Authors:  Daniel A C Frattarelli; Michael D Reed; George P Giacoia; Jacob V Aranda
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Aspergillus granuloma of the trigeminal ganglion.

Authors:  C M Wiles; R S Kocen; L Symon; F Scaravilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-05       Impact factor: 10.154

10.  Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum.

Authors:  E Martin; F Maier; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.